Atherothrombosis {#S0001}
================

Atherosclerotic plaque rupture or erosion is thought to be the initial step in the development of acute coronary syndrome (ACS). At the site of vascular injury (due to plaque rupture) exposed subendothelial matrix recruits and activates platelets \[[@CIT0001]\]. Platelets adhere to exposed collagen and von Willebrand factor (vWF). Via the platelet glycoprotein (GP)-VI receptor and integrin α2β1, collagen can directly bind to and activate platelets, which leads to release of contents from the dense granules to the extracellular surrounding. Dense granules mostly consist of platelet agonists such as adenosine diphosphate (ADP), epinephrine, serotonin, thrombin, thromboxane A~2~, which in turn promote aggregation, recruitment, and further activation of circulating platelets. The α-granules contain fibrinogen, factor V and P-selectin. ADP binds to platelet P2Y12 and P2Y1 receptors and by that amplifies the effect of other agonists such as thrombin \[[@CIT0001]--[@CIT0003]\]. Activation induces changes in platelet shape, increase of surface by pseudopodia and secretion of further storage products. In the final step, GP IIb/IIIa is converted into its active form, which binds fibrinogen and vWF, leading to stable platelet aggregates and subsequent thrombus formation \[[@CIT0004]\]. Additionally, the vascular injury exposes tissue factor which initiates the extrinsic clotting cascade and leads to generation of more thrombin and the propagation of the fibrin clot \[[@CIT0005]\].

P2Y~12~ receptor {#S0002}
================

The P2Y~12~ receptor is a member of the P2Y purinergic G protein-coupled receptors (GPCR) family, which is activated by ADP, thromboxane A~2~ and the PAR-1 receptor agonists \[[@CIT0006], [@CIT0007]\]. Activation of the P2Y~1~ receptor by ADP initiates a weak and transient phase of platelet aggregation whereas binding of ADP to the P2Y~12~ amplifies dense granule secretion, expression of P-selectin and platelet aggregation \[[@CIT0008]\]. Further stimulation of the P2Y~12~ receptor sustains the activation of the GP IIb/IIIa and GP Ia/IIa receptors and stabilization of platelet aggregates \[[@CIT0009], [@CIT0010]\].

P2Y~12~ receptor antagonism {#S0003}
===========================

Combination of aspirin with P2Y~12~ receptor antagonists has been proven in a multitude of trials to have a favourable synergistic effect in patients after coronary stent implantation \[[@CIT0011]\]. To date, ticlopidine, clopidogrel, prasugrel, ticagrelor and an intravenous compound, cangrelor, have been approved by the Food and Drug Administration (FDA) \[[@CIT0001], [@CIT0012], [@CIT0013]\].

Ticlopidine {#S0004}
===========

Ticlopidine, a first-generation thienopyridine, was the first FDA-approved P2Y~12~ receptor inhibitor in clinical use \[[@CIT0014]\]. It was the first drug that showed a decrease in major cardiovascular events in patients after stroke compared to aspirin or placebo, and in patients after percutaneous coronary intervention (PCI) compared to warfarin-based regimens \[[@CIT0015]\]. Nevertheless, severe side effects like aplastic anaemia and agranulocytosis and slow onset of action limit the use of the compound and have led to the development of clopidogrel \[[@CIT0016]\].

Clopidogrel {#S0005}
===========

Clopidogrel, a second-generation thienopyridine-type irreversible inhibitor of the P2Y~12~ receptor, has a more favourable safety profile compared to the ticlopidine. It is a pro-drug, requiring enteric and hepatic transformation by the cytochrome P450 (CYP) system to exert its antiplatelet effect. After absorption, up to 85% of clopidogrel is hydrolyzed by carboxyesterase-1 to an inactive metabolite, SR26334. The remaining approx. 15% of clopidogrel are metabolized to the active compound, R-130964, in a two-step process *via* formation of 2-oxo-clopidogrel. CYP 2C19 seems to have the most prominent role in this process, with less involvement of CYP2B6, CYP1A2, CYP3A/A5, and CYP2C9 \[[@CIT0017], [@CIT0018]\] ([Figure 1](#F0001){ref-type="fig"}). After administration of a 600 mg clopidogrel loading dose, the maximum achievable inhibition of ADP-induced platelet aggregation of 40--60% is achieved within 2 to 6 h \[[@CIT0019]\].

![Metabolism of P2Y12 receptor inhibitors\
ADP -- adenosine diphosphate, CYP -- cytochrome 450.](PWKI-11-26089-g001){#F0001}

Next generation P2Y~12~ inhibitors {#S0006}
==================================

Despite the proven benefits of aspirin and clopidogrel, a non-negligible proportion of patients continue to experience recurrent ischemic events. These clinical failures have been attributed to response variability and to a relatively slow onset of action with clopidogrel and have prompted the development of new oral P2Y~12~ inhibitors. Additionally, it has been shown that a moderate platelet inhibition by clopidogrel is insufficient to suppress an increase in ADP-induced platelet aggregation in the midmorning, in the period when myocardial infarction (MI), stroke and sudden cardiac death occur the most frequently \[[@CIT0020]--[@CIT0023]\]. Both prasugrel and ticagrelor have shown to have a more consistent, rapid and potent P2Y~12~ receptor inhibition than clopidogrel, which translated into reduction in the ischemic events at the costs of bleeding events \[[@CIT0012], [@CIT0024]--[@CIT0029]\].

Prasugrel {#S20007}
---------

Prasugrel is a third generation thienopyridine, which acts as an irreversible inhibitor of the P2Y~12~ receptor. Like clopidogrel, prasugrel is a pro-drug and requires hepatic bioactivation. The active metabolite is formed in a single-step oxidation via various CYP isoenzymes (CYP3A4/5, CYP2B6, CYP2C19, CYP2C9) \[[@CIT0030]\] ([Figure 1](#F0001){ref-type="fig"}).

It\'s worth noting that the known functional genetic CYP variants do not significantly affect formation of the active metabolite of prasugrel, that is faster and more efficient resulting in greater *in vivo* antiplatelet potency compared to clopidogrel \[[@CIT0031], [@CIT0032]\].

Ticagrelor {#S20008}
----------

Ticagrelor, a cyclopentyl-triazolo-pyrimidine, is an oral antagonist of the P2Y~12~ receptor, and unlike clopidogrel and prasugrel it is an active, noncompetitive antagonist of the P2Y~12~ receptor. As an active drug ticagrelor does not require hepatic bioactivation, but has a metabolite (AR-C124910XX) formed by metabolism via CYP3A4, with also anti-aggregatory effects \[[@CIT0033]\] ([Figure 1](#F0001){ref-type="fig"}). Genetic factors including *CYP2C19* and *ABCB1* polymorphisms do not influence the clinical outcome of ticagrelor-treated patients \[[@CIT0034]\]. Ticagrelor is active immediately after oral administration, which results in a more rapid onset of action and a more pronounced platelet inhibition compared to clopidogrel \[[@CIT0035]\].

The unprecedented mortality benefits observed in the PLATO trial, despite only a moderate decrease in the occurrence of MI, led to a hypothesis that ticagrelor therapy was associated with off-target effects \[[@CIT0036]\]. Since P2Y~12~ receptors were identified on vascular smooth muscle cells (VSMCs), we and others have earlier demonstrated in animal and human models that ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced VSMC contraction \[[@CIT0037]\]. Additionally, other groups have demonstrated that ticagrelor inhibited the uptake of adenosine by human erythrocytes \[[@CIT0038]\] and also induced the release of adenosine triphosphate from human erythrocytes, that is, followed by its degradation to adenosine \[[@CIT0039]\]. The former mechanism was proposed to explain the enhancement of adenosine-induced increase in coronary blood flow observed in a canine model by ticagrelor \[[@CIT0038]\].

High on-treatment platelet reactivity {#S0009}
=====================================

In clinical practice, antiplatelet drugs are administered to patients at standard doses, without monitoring their pharmacological response as it is done in case of warfarin therapy guided by INR-control \[[@CIT0040]\]. This fixed-dose or better "one size fits all" approach with clopidogrel therapy is a remnant of clinical trials and does not take the inter-individual pharmacodynamic variability of ADP-pathway inhibitors into account \[[@CIT0041]\]. Starting in 2003, studies suggested that the level of platelet inhibition, especially by clopidogrel, considerably varies between patients \[[@CIT0041], [@CIT0042]\].

Dependent on the assay used and the population studied, up to 25--50% of clopidogrel-treated patients fail to show adequate pharmacological response to clopidogrel and are not adequately protected from major adverse cardiac events (MACE) \[[@CIT0043]--[@CIT0045]\]. There is robust data showing an association between clopidogrel non-responsiveness or high on-treatment platelet reactivity (HPR) and adverse ischemic events, with the strongest association for short-term thrombotic events, like acute and subacute stent thrombosis, in patients after PCI \[[@CIT0042], [@CIT0046]--[@CIT0055]\]. Nevertheless, the routine measurement of platelet reactivity has not been widely implemented and recommended in the guidelines. At least 40 studies demonstrated that ADP-induced platelet function testing is the best predictor of ischemic events in clopidogrel non-responders \[[@CIT0054], [@CIT0056]--[@CIT0058]\]. Likewise, measurement of platelet function by light transmission aggregometry (LTA) in patients undergoing coronary stenting might predict adverse events \[[@CIT0059]--[@CIT0062]\]. Other tests, including the new generation impedance aggregometry test (Multiplate, MEA), VerifyNow™ and the vasodilator stimulated phosphoprotein (VASP) phosphorylation assay, have confirmed the association between poor clopidogrel responsiveness and increased risk of cardiac ischemic events during short- and long- term follow-up \[[@CIT0046], [@CIT0048], [@CIT0063]--[@CIT0069]\]. Nevertheless, lack of consensus concerning optimal method to quantify HPR and the best cut-off value associated with clinical risk has hindered the consideration of platelet function testing (PFT) in clinical guidelines. However, a recent analysis involving more than 20,000 patients after PCI tested uniformly-defined cutoff values for three relatively well-standardized assays (MEA, VerifyNow and VASP) and identified sharp cut points for HPR that were highly significant predictors of stent thrombosis and cardiovascular mortality \[[@CIT0070]\].

Although new platelet aggregation inhibitors were invented to overcome HPR, it has been shown that this phenomenon is not exclusively true for clopidogrel treatment. In the acute phase of ST-elevation myocardial infarction (STEMI) 37% of the patients treated with prasugrel and 46% treated with ticagrelor exhibited HPR \[[@CIT0069], [@CIT0071]--[@CIT0076]\]. Interestingly, a recent study has indicated that 12% of prasugrel-treated patients presented with the HPR phenotype \[[@CIT0077]\], which might be explained by the fact that 43% of included patients displayed HPR under clopidogrel treatment and were switched to prasugrel \[[@CIT0077]\]. Similarly, the TAILOR study as well as randomized trials in haemodialysis patients have shown that up to 20% of patients continued to exhibit HPR despite switch from clopidogrel to prasugrel \[[@CIT0073], [@CIT0074], [@CIT0078]\]. Noteworthy, in the MADONNA study, direct switch to prasugrel from clopidogrel was associated with a satisfactory level of platelet inhibition by prasugrel in all patients \[[@CIT0079]\]. Not surprisingly, however, the platelet inhibitory effect in patients treated with therapeutic hypothermia after cardiac arrest was reduced in prasugrel and ticagrelor treated patients reaching an incidence of HPR of 32% and 30%, respectively \[[@CIT0080]\]. Interestingly, some studies indicated that in ACS patients with HPR while on clopidogrel ticagrelor produced stronger platelet inhibition compared with prasugrel \[[@CIT0081]\]. Noteworthy, switching from ticagrelor maintenance dose to prasugrel maintenance dose was associated with a lower level of platelet inhibition as compared to continued ticagrelor therapy \[[@CIT0082]\]. Nevertheless, at day 7 there was no difference in HPR frequency between the prasugrel and ticagrelor groups \[[@CIT0082]\]. In ACS patients one month after the event ticagrelor was more effective than prasugrel in a pharmacodynamic study \[[@CIT0083]\]. Interestingly, the antiplatelet activity of ticagrelor\'s active metabolite was more potent compared to ticagrelor or prasugrel\'s active metabolite in both humans and nonhuman primates \[[@CIT0084]\].

Therefore, although the rate of HPR is lower with novel P2Y~12~-inhibitors, it is not an exclusive feature of clopidogrel. While clinical, genetic and demographic variables associated with HPR in clopidogrel-treated subjects are well defined and the worse clinical course in such patients is unquestionable, such factors and clinical impacts should be investigated and clarified in future trials in case of prasugrel and ticagrelor.

Clinical factors associated with HPR {#S0010}
====================================

Drug-drug interactions, obesity, renal dysfunction, diabetes mellitus (DM), higher age, reduced left ventricular function, inflammation and the presence of an ACS are all associated with inadequate response to clopidogrel therapy and consequential HPR \[[@CIT0085]--[@CIT0090]\]. For further risk stratification, it has been suggested to use scoring systems that can integrate clinical risk factors and genetic variants identified by path models \[[@CIT0091], [@CIT0092]\].

Drug-drug interactions {#S0011}
======================

It has been shown that certain proton pump inhibitors such as omeprazole, calcium channel blockers, ketoconazole and rifampicin may significantly influence clopidogrel metabolism \[[@CIT0087], [@CIT0093]--[@CIT0102]\]. Interestingly, morphine co-medication in ACS is a strong predictor of HPR in patients treated with clopidogrel, prasugrel and ticagrelor. This effect might be partially explainable by the impaired or delayed absorption of those drugs induced by opioid-induced gastroparesis \[[@CIT0076], [@CIT0103], [@CIT0104]\].

Diabetes mellitus {#S0012}
=================

Among all clinical risk factors accounting for HPR, DM has a unique position. DM is a strong independent predictor of short-term and long-term recurrent ischemic events and mortality in the ACS setting \[[@CIT0105]\]. The reported negative impact on mortality includes all ACS subtypes and especially the increased risk for short-term ischemic events suggests an important role of platelet activation-aggregation.

It is well evidenced that platelets of DM patients exhibit an increased reactivity, caused by dysregulation of several signalling pathways by hyperglycaemia, insulin resistance, metabolic conditions and inflammation \[[@CIT0106]\].

Direct insulin effect on platelets {#S20013}
----------------------------------

In general, insulin exhibits anti-aggregatory effects and this antithrombotic effects are diminished in diabetic patients \[[@CIT0107]\]. Insulin can exhibit direct anti-aggregatory effect via attenuation of the thrombin-induced Ca^2+^ response and the release of ADP as well as inhibition of the P2Y~12~ receptor \[[@CIT0108], [@CIT0109]\]. Furthermore, it enhances the platelet inhibitory effects of prostaglandin (PG) E1 and I2 ([Figure 2](#F0002){ref-type="fig"}) \[[@CIT0110]\].

![Effects of insulin on blood cells\
PGE1 -- prostaglandin E1, PGI2 -- prostaglandin I2, NO -- nitric oxide, ADP -- adenosine diphosphate, PAI-1 -- plasminogen activator inhibitor 1.](PWKI-11-26089-g002){#F0002}

Hyperglycaemia {#S20014}
--------------

Hyperglycaemia has been shown to increase platelet reactivity in various ways ([Figure 3](#F0003){ref-type="fig"}). It induces P-selectin expression, alters membrane fluidity with subsequent platelet adhesion and activates protein C \[[@CIT0106], [@CIT0111]\]. In DM patients with ACS, glucose lowering therapy is proven beneficial independent of the treatment strategy \[[@CIT0112], [@CIT0113]\].

![Effects of hyperglycaemia on platelets](PWKI-11-26089-g003){#F0003}

Insulin deficiency and resistance {#S20015}
---------------------------------

Both insulin receptors and the insulin-like growth factor-1 (IGF-1) are expressed on thrombocytes. Binding of insulin to the platelets' insulin receptor increases surface expression of adenylate cyclise-linked prostacyclin receptor, but due to the low Insulin receptor expression, the effect is negligible. IGF-1 is stored in the α-granules of platelets, which may contribute to the amplification of platelet aggregation after alpha granule release \[[@CIT0114]\]. Other mechanisms how insulin resistance affect platelet aggregation include increased intracellular calcium with chanced platelet degranulation, impaired response to prostacyclin and nitric oxide \[[@CIT0115], [@CIT0116]\].

Metabolic conditions {#S20016}
--------------------

The DM is often accompanied by obesity, dyslipidemia, and enhanced systemic inflammation, every single one of which may contribute to the increased platelet reactivity. Obesity may enhance platelet aggregation via similar pathomechanisms as insulin resistance: higher mean platelet volume, high blood leptin, increased intracellular calcium concentration \[[@CIT0106]\].

HPR in diabetic patients {#S20017}
------------------------

A multitude of trials have proven the benefit of clopidogrel in combination with aspirin in post-ACS DM patients. Nevertheless, HPR under clopidogrel therapy is more prevalent in diabetic compared with non-diabetic patients, especially in those requiring insulin therapy \[[@CIT0105], [@CIT0107]\]. Similar factors leading to increased platelet reactivity in DM patients also cause HPR to clopidogrel. To date, only small *in vitro* and *ex vivo* studies have identified the following factors to cause HPR: lack of response to insulin in platelets, changes in calcium metabolism, P2Y~12~ receptor signalling upregulation, increased exposure to ADP, and increased platelet turnover \[[@CIT0106], [@CIT0117], [@CIT0118]\].

Another interesting mechanism for impaired P2Y~12~ inhibition mediated by clopidogrel among DM patients has been linked to attenuation of clopidogrel's pharmacokinetics, which was characterized by lower plasma levels of clopidogrel active metabolite as compared with non-diabetic patients \[[@CIT0119]\].

Low on-treatment platelet reactivity and the therapeutic window concept {#S0018}
=======================================================================

Some studies postulated that there might be a therapeutic window for P2Y~12~ receptor blockers, indicating that while HPR is associated with thrombotic events, low on-treatment platelet reactivity (LPR) may be related to bleeding events \[[@CIT0061], [@CIT0064], [@CIT0065], [@CIT0120]--[@CIT0122]\]. The two sides of the coin regarding P2Y~12~-inhibition, i.e. higher risk for thrombosis in HPR and higher risk for bleeding in LPR suggest that a sweet spot may exist for P2Y~12~-inhibition. Validation of such therapeutic window with patients having optimal platelet reactivity was recently reported in a collaborative analysis including more than 20,000 patients \[[@CIT0070]\]. According to the results, patients with LPR had an absolute 1.2% lower risk for stent thrombosis and 2.7% lower risk for bleeding, compared to HPR and LPR, respectively \[[@CIT0070]\].

Test systems used for assessment of the effect of antiplatelet drugs {#S0019}
====================================================================

The effect of clopidogrel on platelet function can be measured by platelet function testing and corresponds to the phenotype of its response. There are several test systems available for monitoring the effect of antiplatelet drugs, all characterizing different pathways of platelet activation, unfortunately with no option to reflect the complexity of platelet biology.

Platelet aggregometry {#S20020}
---------------------

Platelet aggregometry is based on the stimulation of platelet aggregation with different agents. There are two commercially available techniques: optical and impedance aggregometry.

Light transmission aggregometry {#S20021}
-------------------------------

Light transmission aggregometry (LTA) used to be the most widespread platelet function test. P2Y~12~ receptor inhibition is measured by adding ADP and the change in the light transmittance is recorded. The maximal aggregation and the final aggregation responses can be measured and expressed as percentage ([Table I](#T0001){ref-type="table"}). The widespread use and the reported good correlation between the measured aggregation responses and adverse events are the most important advantages of optical aggregometry. Time-consuming centrifugation steps as well as the large sample volume needed and variable reproducibility make this test less favourable. The proposed cutoff for HPR is \> 70% of the maximal ADP-induced aggregation, but as LTA is not standardized according to the concentration of agonist, centrifuging time and speed, this sharp cut point is not generalizable for different centers. LTA is able to predict ischemic events with a sensitivity between 60--79%, with a specificity of 59--82% and an area under the receiver operating curve (AUC) of 0.73--0.85, and an odds ratio (OR) for ischemic events in the range of 3--35 \[[@CIT0052], [@CIT0056], [@CIT0059], [@CIT0123]--[@CIT0125]\]. Additionally, LTA has been shown to predict stent thrombosis and bleeding events \[[@CIT0047], [@CIT0049], [@CIT0051], [@CIT0052]\].

###### 

Studies investigating the association of ischemic or bleeding events and clopidogrel response with use of light transmission aggregrometry (LTA)

  Study author/acronym                   Method:agonist   *N*    Population                  Follow-up      Outcome               OR/HR   Cut-off value (%)   Prevalence of HPR/LPR (%)   AUC    PPV (%)   NPV (%)   Sensitivity (%)   Specificity (%)
  -------------------------------------- ---------------- ------ --------------------------- -------------- --------------------- ------- ------------------- --------------------------- ------ --------- --------- ----------------- -----------------
  **Thrombosis**                                                                                                                                                                                                                       
  Matetzky *et al.* \[[@CIT0042]\]       LTA:ADP          60     PCI+STEMI                   6 months       MACE                  6.00    103                 25                                                                       
  Gurbel *et al.* \[[@CIT0056]\]         LTA:ADP          297    Elective PCI                2 years        MACE                  3.90    46                  30                          0.77                       63                82
  CREST \[[@CIT0053]\]                   LTA:ADP          100    History of ST vs. no ST                                                  42                  60                                                                       
  PREPARE-POST STENTING \[[@CIT0123]\]   LTA:ADP          192    Elective PCI                6 months       MACE                  2.70    67                  25                                                     37                79
  CLEAR PLATELETS \[[@CIT0062]\]         LTA:ADP          120    Elective PCI                In hospital    Periprocedural MI             50                                                                                           
  CLEAR PLATELETS-2 \[[@CIT0058]\]       LTA:ADP          200    Elective PCI                In hospital    Periprocedural MI             40                                                                                           
  Frere *et al.* \[[@CIT0124]\]          LTA:ADP          195    NSTE-ACS+PCI                1 month        MACE                  8.00    70                  27                          0.74   21        98        79                76
  Cuisset *et al.* \[[@CIT0052]\]        LTA:ADP          598    NSTE-ACS+PCI                1 month        ST                    5.80    67                                              0.70   4         99        70                68
  Cuisset *et al.* \[[@CIT0187]\]        LTA:ADP          106    NSTE-ACS+PCI                1 month        MACE                  22.40   70                  25                                                                       
  Cuisset *et al.* \[[@CIT0054]\]        LTA:ADP          190    NSTEMI+PCI                  In hospital    Periprocedural MI     1.80    70                  22                                                                       
  POPULAR \[[@CIT0059]\]                 LTA:ADP          1049   Elective PCI                1 year         MACE                  2.09    43                  42                          0.73   12        94        60                59
  POPULAR \[[@CIT0188]\]                 LTA:ADP          921    Elective PCI                1 year         MACE                  2.65    43                  15                                                                       
  Bliden *et al.* \[[@CIT0125]\]         LTA:ADP          100    Elective PCI                1 year         MACE                  34.60   50                  22                          0.86   73        91                          
  Lev *et al.* \[[@CIT0057]\]            LTA:ADP          150    Elective PCI                In hospital    Myonecrosis           1.87    70                  24                                                                       
  Gori *et al.* \[[@CIT0051]\]           LTA:ADP          746    PCI+DES                     6 months       ST                    3.15    70                  12                                                                       
  Geisler *et al.* \[[@CIT0189]\]        LTA:ADP          379    PCI                         3 months       MACE, death           4.90    70                  6                                                                        
  Geisler *et al.* \[[@CIT0047]\]        LTA:ADP          1019   PCI                         3 months       ST                    2.21    42.5                33                                                                       
  Geisler *et al.* \[[@CIT0086]\]        LTA:ADP          1092   PCI                         1 month        MACE                  1.71    47                  33                                                                       
  EXCELSIOR \[[@CIT0060]\]               LTA:ADP          802    Elective PCI                1 month        MACE                  6.70    32                  25                                                                       
  EXCELSIOR \[[@CIT0190]\]               LTA:ADP          797    Elective PCI                1 year         MACE                  3.0     14                  27                                                                       
  Buonamicci *et al.* \[[@CIT0049]\]     LTA:ADP          804    PCI+DES                     6 months       ST                    3.08    70                  13                                                                       
  Migliorini *et al.* \[[@CIT0050]\]     LTA:ADP          215    PCI                         3 years        CD, ST                3.82    70                  19                                                                       
  Wang *et al.* \[[@CIT0191]\]           LTA:ADP          386    Elective PCI+DES            1 year         MACE                  2.44    10 difference       17                                                                       
  Wenaweser *et al.* \[[@CIT0192]\]      LTA:ADP          82     History of ST vs. no ST     Case/control                                 10 difference                                                                                
  RECLOSE 2-ACS \[[@CIT0061]\]           LTA:ADP          1789   ACS+PCI                     2 years        MACE                  1.49    70                  16                                 15        91                          
  **Bleeding**                                                                                                                                                                                                                         
  Parodi *et al.* \[[@CIT0061]\]         LTA:ADP          298    PCI+prasugrel               6 months       TIMI major bleeding   0.91    40                  32                                                                       
  Chen *et al.* \[[@CIT0193]\]           LTA:ADP          45     Surgery under clopidogrel                  Blood transfusion             40                                                                                           

ADP -- adenosine diphosphate, AUC -- area under the curve (of the receiver operating curve -- c-index), PPV -- positive predictive value, NPV -- negative predictive value, HPR -- high platelet reactivity (prevalence is given for studies investigating thrombotic events), LPR -- low platelet reactivity (prevalence is given for studies investigating bleeding events), PCI -- percutaneous coronary intervention, NSTE-ACS -- non ST-elevation acute coronary syndrome, STEMI-ST -- elevation myocardial infarction, MACE -- major adverse cardiac events, MI -- myocardial infarction, ST -- stent thrombosis, DES -- drug eluting stent, CD -- cardiac death, TIMI -- thrombolysis in myocardial infraction, NS -- not significant.

Impedance aggregometry: multiple electrode aggregometry {#S20022}
-------------------------------------------------------

Multiple electrode aggregometry (MEA) is measuring whole blood platelet aggregation. ADP is used as agonist and, depending on the test, the antagonist PGE1 may be added (high sensitivity ADP test (ADP-HS)). Changes in the electrical impedance caused by adhesion and aggregation of platelets on two independent electrode-set surfaces is measured and expressed as U (units) \[[@CIT0100], [@CIT0126], [@CIT0127]\]. The cut-off values to separate patients with HPR in prior studies were around 46-50 U ([Table II](#T0002){ref-type="table"}) \[[@CIT0100], [@CIT0126], [@CIT0127]\]. MEA can predict stent thrombosis quite effectively (OR: 9--37; AUC: 0.78--0.92; sensitivity: 70--90% and specificity: 84--100%) \[[@CIT0046], [@CIT0048], [@CIT0063]\]. Similarly to LTA, MEA has been shown to predict major bleedings (AUC: 0.61--0.74; sensitivity: 72--77% and specificity: 62--66%) \[[@CIT0064], [@CIT0065], [@CIT0128], [@CIT0129]\].

###### 

Studies investigating the association of ischemic or bleeding events and clopidogrel response with use of Multiplate Electrode Aggregometry (MEA)

  Study author/acronym                          Method:agonist   *N*    Population                  Follow-up     Outcome                  OR/HR   Cut-off value       Prevalence of HPR/LPR (%)   AUC    PPV (%)   NPV (%)   Sensitivity (%)   Specificity (%)
  --------------------------------------------- ---------------- ------ --------------------------- ------------- ------------------------ ------- ------------------- --------------------------- ------ --------- --------- ----------------- -----------------
  **Thrombosis**                                                                                                                                                                                                                                
  Sibbing *et al*. \[[@CIT0046]\]               MEA:ADP          1608   Elective PCI                1 month       ST                       9.40    468AU\*min = 47 U   20                          0.78                       70                84
  Sibbing *et al*. \[[@CIT0064], [@CIT0065]\]   MEA:ADP          2533   Elective PCI                1 month       ST                       0.40    468AU\*min = 47 U   17                                                                       
  Eshtehardi *et al*. \[[@CIT0066]\]            MEA:ADP          219    PCI                         1 month       MACE                             309AU\*min = 31 U   15                                                                       
  Müller-Schunk *et al*. \[[@CIT0194]\]         MEA:ADP          50     Neurointerventional stent                 ST+TIA/stroke                    52 U                28                                                                       
  Siller-Matula *et al*. \[[@CIT0195]\]         MEA:ADP          403    PCI                         1 year        MACE                     1.75    48 U                19                          0.60                                         
  PEGASUS-PCI \[[@CIT0063]\]                    MEA:ADP          416    PCI                         1 year        ST, MACE                         46 U                38                          0.78   7         100       70                67
  Dineva *et al*. \[[@CIT0067]\]                MEA:ADP          603    PCI                         1 month       ST                       24.3    46 U                18                          0.86                       84                78
  Siller-Matula *et al*. \[[@CIT0048]\]         MEA:ADP+PGE1     416    PCI                         6 months      ST                               54 U                14                          0.92   5         100       86                100
  PEGASUS-PCI \[[@CIT0063]\]                    MEA:ADP+PGE1     416    PCI                         1 year        ST, MACE                 36.9    48 U                19                          0.90   13        100       90                83
  **Bleeding**                                                                                                                                                                                                                                  
  Rahe-Meyer *et al*. \[[@CIT0128]\]            MEA:ADP          60     Cardiac surgery             In hospital   Blood Transfusion                13 U                33                          0.74                       77                63
  Sibbing *et al*. \[[@CIT0064], [@CIT0065]\]   MEA:ADP          2533   PCI                         In hospital   TIMI major bleeding      3.50    188AU\*min = 19 U   38                          0.61   2         99        62                62
  Ranucci *et al*. \[[@CIT0129]\]               MEA: ADP         87     Thienopyridine treatment    In hospital   Postoperative bleeding           31 U                40                          0.71   29        92        72                66
  PEGASUS-PCI \[[@CIT0063]\]                    MEA:ADP+PG       416    PCI                         1 year        TIMI major bleeding      Ns      20 U                                                                                         

ADP -- adenosine diphosphate, PGE1 -- prostaglandin E1, AUC -- area under the curve (of the receiver operating curve -- c-index), PPV -- positive predictive value, NPV -- negative predictive value, HPR -- high platelet reactivity (prevalence is given for studies investigating thrombotic events), LPR -- low platelet reactivity (prevalence is given for studies investigating bleeding events), PCI -- percutaneous coronary intervention, MACE -- major adverse cardiac events, ST -- stent thrombosis, TIA -- transient ischemic attack, TIMI -- thrombolysis in myocardial infraction, NS -- not significant.

VASP phosphorylation {#S20023}
--------------------

Measurement of VASP phosphorylation, that is a second messenger in one of the intracellular signalling pathways downstream of the P2Y~12~ receptor, forms the basis of this assay (BioCytex, Marseille, France) \[[@CIT0130], [@CIT0131]\]. Serine 239-phosphorylated VASP is labelled with a monoclonal antibody followed by a secondary fluorescein isothiocyanate (FITC)-conjugated polyclonal goat-anti-mouse antibody and then measured using a flow cytometer. Platelet reactivity is expressed as platelet reactivity index (PRI%). Due to this unique technique, the VASP assay is highly reproducible even after 24 h of sample storage \[[@CIT0090]\]. The VASP assay is the most specific assay for P2Y~12~ signalling, because it evaluates the extent of P2Y~12~ receptor inhibition without influencing the P2Y~1~ receptor with agonist. The cut-off for VASP to separate patients with HPR is 50% (70) PRI \[[@CIT0093]\]. A positive VASP test result corresponded to an OR = 1--23 \[[@CIT0124], [@CIT0131]\] to develop a stent thrombosis or MACE (AUC: 0.55--0.79) with high sensitivity (70--100%) \[[@CIT0048], [@CIT0132]\] but low specificity (25--37%) ([Table III](#T0003){ref-type="table"}).

###### 

Studies investigating the association of ischemic or bleeding events and clopidogrel response with use of vasodilator activated phosphoprotein assay (VASP)

  Study author/acronym                    Method:agonist   *N*   Population                Follow-up             Outcome                          OR/HR   Cut-off value (%)   Prevalence of HPR/LPR (%)   AUC    PPV (%)   NPV (%)   Sensitivity (%)   Specificity (%)
  --------------------------------------- ---------------- ----- ------------------------- --------------------- -------------------------------- ------- ------------------- --------------------------- ------ --------- --------- ----------------- -----------------
  **Thrombosis**                                                                                                                                                                                                                                       
  Bonello *et al*. \[[@CIT0132]\]         VASP assay       144   PCI                       6 months              MACE                                     50                  20                          0.55             100       100               25
  Bonello *et al*. \[[@CIT0069]\]         VASP assay       301   ACS+PCI+prasugrel         1 month               MACE                             23.0    53.5                25                          0.86   92        100       88                77
  Siller-Matula *et al*. \[[@CIT0048]\]   VASP assay       416   PCI                       6 months              ST                               NS      42                  63                          0.60   1         100       100               37
  PEGASUS-PCI \[[@CIT0063]\]              VASP assay       416   PCI                       1 year                ST, MACE                         NS      42                  62                          0.62   3         98        70                38
  Blindt *et al*. \[[@CIT0131]\]          VASP assay       99    PCI at high ST risk       6 months              ST                               1.16    48                                              0.79                       80                73
  Frere *et al*. \[[@CIT0124]\]           VASP assay       195   NSTE-ACS+PCI              1 month               MACE                             11.18   53                  54                          0.73   12        99        93                50
  Barragan *et al*. \[[@CIT0196]\]        VASP assay       46    History of ST vs. no ST   1 month               ST                                       50                                                                                           
  Cuisset *et al*. \[[@CIT0052]\]         VASP assay       598   NSTE-ACS+PCI              1 month               ST                               NS                                                      0.61                                         
  WILMAA \[[@CIT0068]\]                   VASP assay       300   PCI                       6 months              MACE                             1.04    60                  62                          0.68   8         99        94                37
  **Bleeding**                                                                                                                                                                                                                                         
  Cuisset *et al*. \[[@CIT0197]\]         VASP             597   NSTEMI+PCI                1 month               TIMI bleeding non-CABG related           40                  25                                                                       
  Mokhtar *et al*. \[[@CIT0121]\]         VASP             346   PCI                       In hospital           TIMI major bleeding non-CABG     0.96                                                                                                 
  Michelson *et al*. \[[@CIT0071]\]       VASP             125   ACS+PCI                   \> 3 days after PCI   Serious bleedings                0.97    50                                                                                           

AUC -- area under the curve (of the receiver operating curve -- c-index), PPV -- positive predictive value, NPV -- negative predictive value, PCI -- percutaneous coronary intervention, NSTE-ACS -- non ST-elevation acute coronary syndrome, MACE -- major adverse cardiac events, ST -- stent thrombosis, TIMI -- thrombolysis in myocardial infraction, CABG -- coronary artery bypass graft, HPR -- high platelet reactivity (prevalence is given for studies investigating thrombotic events), LPR -- low platelet reactivity (prevalence is given for studies investigating bleeding events), NS -- not significant.

VerifyNow™ {#S20024}
----------

The VerifyNow™ assay (Accumetrics, San Diego, USA) measures the agonist-induced activation of platelets and their binding to fibrinogen-coated polystyrene beads. Once the platelets have bound to the beads, the platelet-bead complexes fall out of the solution and infrared-light transmittance increases. The assay uses ADP as agonist and PGE1 as antagonist and results are reported as P2Y~12~ reaction units (PRU) \[[@CIT0133]\]. Beside the higher costs, the VerifyNow™ test shares the same advantages as the MEA, such as whole blood test condition, fast preparation time and small blood volume requirement. Although prior studies suggested 235 PRU to separate patients with HPR, data from the largest meta-analysis \[[@CIT0070]\] and a sub-analysis of the GRAVITAS study suggest the benefit of a lower cutoff, 208 PRU ([Table IV](#T0004){ref-type="table"}). VerifyNow™ has been shown to predict MACE (OR = 1--6.5; AUC: 0.56--0.87, sensitivity: 60--80% and specificity: 63--92%; [Table IV](#T0004){ref-type="table"}) and major bleeding events (OR = 0.94; AUC = 0.84, sensitivity: 81% and specificity: 80%) \[[@CIT0120], [@CIT0134], [@CIT0135]\] ([Table IV](#T0004){ref-type="table"}).

###### 

Studies investigating the association of ischemic or bleeding events and clopidogrel response with use of VerifyNow assay

  Study author/acronym                                    Method:agonist   *N*    Population                   Follow-up     Outcome               OR/HR   Cut-off value       Prevalence of HPR/LPR (%)                 AUC                  PPV (%)   NPV (%)   Sensitivity (%)   Specificity (%)
  ------------------------------------------------------- ---------------- ------ ---------------------------- ------------- --------------------- ------- ------------------- ----------------------------------------- -------------------- --------- --------- ----------------- -----------------
  **Thrombosis**                                                                                                                                                                                                                                                                    
  Price *et al*. \[[@CIT0134]\]                           VerifyNow        380    PCI                          6 months      MACE                  6.50    235 PRU             32                                        0.71                           99        78                68
  Campo *et al*. \[[@CIT0120]\]                           VerifyNow        300    PCI                          1 year        MACE                  1.02    239 PRU             13                                        0.87                 43        98        81                92
  Park *et al*. \[[@CIT0198]\]                            VerifyNow        2849   PCI+DES                      2.2 years     MACE                  NS      235 PRU             58                                                                                                   
  Marcucci *et al*. \[[@CIT0135]\]                        VerifyNow        683    ACS+PCI                      1 year        MACE                  2.52    240 PRU             32                                        0.66                 12        96        61                70
  POPULAR \[[@CIT0059]\]                                  VerifyNow        1055   Elective PCI                 1 year        MACE                  2.53    236 PRU             38                                        0.62                 13        94        60                63
  POPULAR \[[@CIT0188]\]                                  VerifyNow        422    Elective PCI                 1 year        MACE                  2.5     236 PRU             25                                                                                                   
  Cuisset *et al*. \[[@CIT0199]\]                         VerifyNow        120    Elective PCI                 In hospital   Periprocedural MI     4.60    \< 15% inhibition   25                                                                                                   
  ARMYDA PRO \[[@CIT0200]\]                               VerifyNow        160    PCI                          1 month       MACE                  6.10    240 PRU             25                                        0.56                                     81                53
  TRILOGY ACS Platelet Function Substudy \[[@CIT0201]\]   VerifyNow        2564   ACS treated conservatively   30 months     MACE                  NS      208 and 230 PRU     Clopidogrel: 45--55% Prasugrel: 10--15%   0.54 (for 178 PRU)                       47                59
  **Bleeding**                                                                                                                                                                                                                                                                      
  Campo *et al*. \[[@CIT0120]\]                           VerifyNow        300    PCI                          1 year        TIMI major bleeding   0.94    85 PRU              25                                        0.84                 21        98        81                80

AUC -- area under the curve (of the receiver operating curve -- c-index), PPV -- positive predictive value, NPV -- negative predictive value, HPR -- high platelet reactivity (prevalence is given for studies investigating thrombotic events), LPR -- low platelet reactivity (prevalence is given for studies investigating bleeding events), PCI -- percutaneous coronary intervention, ACS -- acute coronary syndrome, MACE -- major adverse cardiac events, MI -- myocardial infarction, ST -- stent thrombosis, DES -- drug eluting stent, TIMI -- thrombolysis in myocardial infraction, NS -- not significant.

Platelet Function Analyzer (PFA-100 ™) {#S20025}
--------------------------------------

The PFA-100™ (Dade Behring, Marburg, Germany) measures the time required for occlusion of a capillary tube by platelet aggregates (closure time -- CT) under high shear rates (5000--6000 s^--1^). To measure the effect of ADP antagonists, the membrane is coated with collagen/adenosine diphosphate (CADP) or collagen/ADP/PGE1. To date, there is conflicting data concerning the reproducibility of the test \[[@CIT0136]--[@CIT0138]\]. The normal value for CADP-CT in treatment of naive patients is 65--120 s \[[@CIT0136]\]. Only small studies revealed the usefulness of the device for prediction of MACE (OR = 3--33) in clopidogrel users \[[@CIT0139]--[@CIT0142]\], but other studies found no association with clinical outcomes \[[@CIT0059]\]. A closure time ≤ 72s has a sensitivity of 86%, and specificity of 76% \[[@CIT0142]\] to detect ischemic events ([Table V](#T0005){ref-type="table"}).

###### 

Studies investigating the association of ischemic events and clopidogrel response with use of Cone and Platelet Analyzer (CPA), Plateletworks, Thromboelastography (TAG) or Platelet Function analyser 100 (PFA 100)

  Study author/acronym                   Method:agonist      *N*   Population     Follow-up   Outcome    OR/HR   Cut-off value   Prevelance of HPR (%)   AUC    PPV (%)   NPV (%)   Sensitivity (%)   Specificity (%)
  -------------------------------------- ------------------- ----- -------------- ----------- ---------- ------- --------------- ----------------------- ------ --------- --------- ----------------- -----------------
  **Thrombosis**                                                                                                                                                                                      
  Matetzky *et al*. \[[@CIT0042]\]       CPA                 60    PCI+STEMI      6 months    MACE       6.00    9% difference   25                                                                   
  POPULAR \[[@CIT0059]\]                 CPA                 910   Elective PCI   1 year      MACE       NS      8.4%            47                      0.56   7         90        56                53
  POPULAR \[[@CIT0059]\]                 CPA:ADP             905   Elective PCI   1 year      MACE       NS      3%              54                      0.53   8         91        44                54
  PEGASUS-PCI \[[@CIT0063]\]             CPA:ADP             416   PCI            1 year      ST, MACE   NS      4.6%            61                      0.62   3         98        90                36
  POPULAR \[[@CIT0059]\]                 Plateletworks       606   Elective PCI   1 year      MACE       2.22    80.5%           43                      0.61   13        94        63                59
  PREPARE-POST STENTING \[[@CIT0123]\]   TEG:ADP             192   Elective PCI   6 months    MACE       22.60   67%             25                                                 74                89
  Bliden *et al*. \[[@CIT0125]\]         TEG:ADP             100   Elective PCI   1 year      MACE       26.80   70%             22                      0.88   67        94                          
  POPULAR \[[@CIT0059]\]                 PFA100:CADP         812   Elective PCI   1 year      MACE       NS      116 s           44                      0.50   5         93        63                44
  PEGASUS-PCI \[[@CIT0063]\]             PFA100:CADP         416   PCI            1 year      ST, MACE   NS      105 s           38                      0.66   4         98        70                61
  Chiu *et al*. \[[@CIT0141]\]           PFA100:CADP         144   PCI            2 years     MACE       5.3     95 s                                                                                 
  Campo *et al*. \[[@CIT0142]\]          PFA100:CADP         135   STEMI+PCI      2 years     MACE       4.5     72 s                                    0.85                       86                76
  Gianetti *et al*. \[[@CIT0139]\]       PFA100:CADP         175   ACS or CAD     6 months    MACE       22.9    82 s            25                                                                   
  Fuchs *et al*. \[[@CIT0140]\]          PFA100:CADP         208   ACS            28 months   MACE       3.2     73 s            25                                                                   
  POPULAR \[[@CIT0059]\]                 PFA100: Innovance   588   Elective PCI   1 year      MACE       NS      299 s           30                      0.56   5         90        61                29

ADP -- adenosine diphosphate, CADP -- collagen-adenosine doiphosphate, HPR -- high platelet reactivity, AUC -- area under the curve (of the receiver operating curve -- c-index), PPV -- positive predictive value, NPV -- negative predictive value, PCI -- percutaneous coronary intervention, ACS -- acute coronary syndrome, STEMI-ST -- elevation myocardial infarction, MACE -- major adverse cardiac events, ST -- stent thrombosis, DES -- drug eluting stent, CAD -- coronary artery disease, NS -- not significant.

Cone and Platelet Analyzer {#S20026}
--------------------------

The Cone and Platelet Analyzer (DiaMed, Cressier, Switzerland) tests thrombocyte adhesion and aggregation under shear stress \[[@CIT0143]\]. Adherent platelets are stained under flow conditions, the percentage of surface coverage (SC) and the average size (AS) of the objects are determined \[[@CIT0144]\]. The variability is relatively low (\< 5%). To date, no study could show that the CPA is sensitive enough to predict ischemic events in clopidogrel-treated patients (AUC: 0.53--0.62; [Table V](#T0005){ref-type="table"}).

Plateletworks {#S20027}
-------------

The Plateletworks (Helena Laboratories, Beaumont, Texas) is based on counting platelets before and after ADP agonist incubation. The ratio between the aggregated platelets after stimulation and the platelet count in the reference tube is used as the degree of platelet aggregation \[[@CIT0059]\]. One study investigated the predictive value of Plateletworks for ischemic events. In the POPULAR study, the Plateletworks assay predicted the composite of major ischemic events with a sensitivity of 63%, specificity of 59% und the AUC of 0.61 ([Table V](#T0005){ref-type="table"}) \[[@CIT0059]\].

Thrombelastography (TEG) {#S20028}
------------------------

The TEG haemostasis analyser (Haemoscope Corp., Niles, Illinois) only measures platelet-fibrin clot strength and is therefore insensitive to P2Y~12~ inhibition and aspirin effect. P2Y~12~ receptor inhibitions can be measured only in modified protocols ([Table V](#T0005){ref-type="table"}) \[[@CIT0123], [@CIT0125], [@CIT0127], [@CIT0145]\].

Limitations of platelet function testing {#S0029}
========================================

It is well known that technical factors, like type of anticoagulant or agonist used, time delay and pipetting errors, can influence the results of platelet testing \[[@CIT0146], [@CIT0147]\].

Beside all technical obstacles related to the procedure itself we must not forget that all these *ex vivo* tests do not reproduce the complexity of thrombocyte activation *in vivo*. Moreover, those tests ignore other platelet activating factors during ACS that might influence outcome, such as cytokines or other paracrine factors \[[@CIT0148]\]. Because of this fact, one cannot assume that an *in vitro* observed clopidogrel effect will show the same efficacy *in vivo*, but vice versa one can prove at least the pharmacological efficacy, because if a drug fails to block ADP-induced aggregation *in vitro*, it will also fail *in vivo*. For that reason, platelet function assays cannot overcome the uncertainty of antithrombotic therapy efficacy in all patients.

It should be emphasized that the consensus regarding the optimal cut-off for HPR is necessary as well as standardization of methods before platelet function testing is introduced in clinical practice.

Genes associated with the response variability to clopidogrel {#S0030}
=============================================================

Cytochrome P450 genetic polymorphisms {#S20031}
-------------------------------------

Due to its complex metabolism, P2Y~12~ inhibitors involve multiple genes in absorption, activation, and inhibition of the receptor. Those detected gene variants have been shown to be associated with both bleeding and ischemic events.

Although CYP2C9 has an integral role in clopidogrel metabolism, the sparse data do not support the genotyping for CYP2C9\*3 for prediction of events \[[@CIT0087], [@CIT0149]\].

*CYP2C19\*2* (loss of function allele), the most common known allele with 30% of Caucasians and up to 50% Asian being carriers, is associated with a reduced antiplatelet effect of clopidogrel and increased risk for adverse cardiovascular events \[[@CIT0087], [@CIT0150]--[@CIT0154]\]. Although the *CYP2C19\*2* allele accounts only for 5--12% of the variation in the response to clopidogrel, several studies have shown an influence of *CYP2C19\*2* on clinical outcome \[[@CIT0091], [@CIT0095], [@CIT0154]--[@CIT0156]\]. Platelet function studies have shown a gene-dose effect in carriers of this polymorphism, showing that increase of dosage led to a sufficient level of platelet inhibition in heterozygous patients, whereas most homozygous patients failed to respond despite daily doses of 300 mg clopidogrel ([Table VI](#T0006){ref-type="table"}) \[[@CIT0157]\].

###### 

Studies investigating the genotype and its association with bleeding or ischemic events

  Study author/acronym                      Polymorphism        *N*        Population                Follow-up   Outcome                 OR/HR   Prevalence (%): carriers   Prevalence (%): homozygote   Prevalence (%): heterozygote
  ----------------------------------------- ------------------- ---------- ------------------------- ----------- ----------------------- ------- -------------------------- ---------------------------- ------------------------------
  **Thrombosis: CYP2C19\*2, 3, \*4, \*5**                                                                                                                                                                
  AFIJI \[[@CIT0152]\]                      2C19\*2             259        MI (\< 45 years of age)   6 months    MACE                    3.69    28                         0                            25
  AFIJI \[[@CIT0150]\]                      2C19\*2             371        MI (\< 45 years of age)   6 years     MACE                    2.26    31                         4                            26
  TRITON TIMI-38 \[[@CIT0153]\]             2C19\*2             1477       PCI+ACS                   15 months   MACE                    1.53    34                                                      
  Oh *et al*. \[[@CIT0202]\]                2C19\*2             2146       PCI+DES                   1 year      MACE                    2.62    47                                                      
  Shuldiner *et al*. \[[@CIT0154]\]         2C19\*2             227        Elective PCI              1 year      MACE                    2.42    33                         2                            31
  RECLOSE \[[@CIT0151]\]                    2C19\*2             772        PCI                       6 months    ST                      3.43    32                         3                            29
  Harmsze *et al*. \[[@CIT0149]\]           2C19\*2             176/420    PCI (ST case/control)     1 year      ST                      1.7     40                         5                            35
  Sibbing *et al*. \[[@CIT0203]\]           2C19\*2             2485       PCI                       30 days     ST                      3.81    27                         2                            25
  Sibbing *et al*. \[[@CIT0165]\]           2C19\*2             127/1439   PCI (ST case/control)     30 days     ST                      2.27    25                         2                            23
  ONASSIST \[[@CIT0087]\]                   2C19\*2             123/246    PCI (ST case/control)                 ST                      1.99    49                         16                           33
  Harmsze *et al*. \[[@CIT0096]\]           2C19\*2             725        Elective PCI              1 year      MACE                    NS      31                         3                            28
  Campo *et al*. \[[@CIT0120]\]             2C19\*2             300        PCI                       1 year      MACE                    NS      27                         2                            25
  CHARISMA \[[@CIT0156]\]                   2C19\*2             4819       CAD or at high risk       2 years     MACE                    NS      15                                                      
  Tiroch *et al*. \[[@CIT0204]\]            2C19\*2             928        MI                        1 year      MACE                    NS      27                         2                            25
  Sawada *et al*. \[[@CIT0205]\]            2C19\*2             100        PCI+DES                   8 months    MACE                    NS      42                                                      
  Tello-Montoliu *et al*. \[[@CIT0206]\]    2C19\*2             428        NSTE-ACS                  6 months    MACE                    NS      28                         3                            25
  Malek *et al*. \[[@CIT0207]\]             2C19\*2             261        ACS                       1 year      Death                   NS      21                         2                            19
  PEGASUS-PCI \[[@CIT0063]\]                2C19\*2             416        PCI                       1 year      ST                      NS      20                         2                            18
  Jeong *et al*. \[[@CIT0159]\]             2C19\*2 and \*3     266        MI                        1 year      MACE                    2.81    45                         8                            37
  FAST-MI \[[@CIT0158]\]                    2C19\*2,3,\*4,\*5   2208       PCI+MI                    1 year      MACE                    1.98    28                         2                            26
  Yamamoto *et al*. \[[@CIT0208]\]          2C19\*2 or \*3      123        CAD                       12 months   MACE                            44                         11                           33
  CURE and ACTIVE \[[@CIT0209]\]            2C19\*2 or \*3      5059       ACS or AF                 1 year      MACE                    NS      20                         2                            18
  PLATO \[[@CIT0210]\]                      2C19\*2-\*8         10285      ACS                       30 days     MACE                    1.37    20                         2                            18
  Harmsze *et al*. \[[@CIT0149]\]           2C9\*3              176/420    PCI (ST case/control)     1 year      ST                      2.4     16                         1                            15
  ONASSIST \[[@CIT0087]\]                   2C9\*3              123/246    PCI (ST case/control)                 ST                      NS      17                         0                            17
  Harmsze *et al*. \[[@CIT0149]\]           CYP3A4\*1B          176/420    PCI (ST case/control)     1 year      ST                      NS      9                          2                            7
  Suh *et al*. \[[@CIT0211]\]               CYP3A5\*3           348        PCI                       6 months    MACE                    4.89    45                                                      
  Harmsze *et al*. \[[@CIT0149]\]           CYP3A5\*3           176/420    PCI (ST case/control)                 ST                      NS      13                         0                            13
  FAST-MI \[[@CIT0158]\]                    CYP3A5\*3           2208       PCI+MI                    1 year      MACE                    NS      17                         1                            16
  Campo *et al*. \[[@CIT0120]\]             CYP3A5\*3           300        PCI                       1 year      MACE                    NS      13                         1                            12
  ONASSIST \[[@CIT0087]\]                   CYP3A5\*3           123/246    PCI (ST case/control)                 ST                      NS      20                         4                            16
  **Bleeding: CYP2C19\*17**                                                                                                                                                                              
  Sibbing *et al*. \[[@CIT0160]\]           2C19\*17            1524       PCI                       30 days     TIMI major bleeding     1.8     41                         5                            36
  Campo *et al*. \[[@CIT0120]\]             2C19\*17            300        PCI                       1 year      TIMI major bleeding     2.3     34                         6                            28
  Harmsze *et al*. \[[@CIT0212]\]           2C19\*17            820        Elective PCI              1 year      TIMI major bleeding     2.7                                                             
  Jeong *et al*. \[[@CIT0159]\]             2C19\*17            266        MI                        1 year      TIMI major bleeding     NS      1                          0                            1
  PLATO \[[@CIT0210]\]                      2C19\*17            10285      ACS                       1 year      Major bleeding          1.25    32                         5                            27
  CURE and ACTIVE \[[@CIT0209]\]            2C19\*17            5059       ACS or AF                 1 year      Major bleeding          NS      34                                                      
  CHARISMA \[[@CIT0156]\]                   2C19\*17            4819       CAD or at high risk       2 years     GUSTO severe bleeding   NS      22                                                      
  PEGASUS-PCI \[[@CIT0063]\]                2C19\*17            416        PCI                       1 year      TIMI major bleeding     NS      34                         4                            30
  **Thrombosis: PON1**                                                                                                                                                                                   
  Bouman *et al*. \[[@CIT0164]\]            PON1                1982       ACS                       1 year      ST                      12.80   54                         13                           41
  EXCELSIOR \[[@CIT0166]\]                  PON1                760        Elective PCI              1 year      MACE                    NS      50                         10                           40
  Sibbing *et al*. \[[@CIT0165]\]           PON1                127/1439   PCI (ST case/control)     30 days     ST                      NS      47                         8                            39
  Campo *et al*. \[[@CIT0163]\]             PON1                300        PCI                       1 month     MACE                    NS      76                         27                           49
  Simon *et al*. \[[@CIT0167]\]             PON1                2210       MI                        1 year      MACE                    NS                                                              
  AFIJI \[[@CIT0150]\]                      PON1                371        MI (\< 45 years of age)   6 years     MACE                    NS      55                         15                           40
  **Thrombosis: ACBC1**                                                                                                                                                                                  
  TRITON TIMI 38 \[[@CIT0213]\]             ABCB1               2932       ACS+PCI                   15 months   MACE                    1.72    73                         23                           50
  FAST-MI \[[@CIT0158]\]                    ABCB1               2208       PCI+MI                    1 year      MACE                    1.72    74                         26                           48
  ONASSIST \[[@CIT0087]\]                   ABCB1               123/246    PCI (ST case/control)                 ST                      2.16    76                         32                           44
  Jaitner *et al*. \[[@CIT0162]\]           ABCB1               66/1408    PCI (ST case/control)                 ST                      NS      78                         29                           49
  Campo *et al*. \[[@CIT0163]\]             ABCB1               300        PCI                       1 year      MACE                    NS      77                         25                           52
  PLATO \[[@CIT0210]\]                      ABCB1               10285      ACS                       1 year      MACE                    NS      76                         27                           49
  Harmsze *et al*. \[[@CIT0149]\]           ABCB1               176/420    PCI (ST case/control)     1 year      ST                      NS      68                         14                           54
  Jeong *et al*. \[[@CIT0159]\]             ABCB1               266        MI                        1 year      MACE                    NS      54                         13                           41
  Spiewak *et al*. \[[@CIT0214]\]           ABCB1               98         ACS+PCI                   1.7 years   MACE                    NS      72                         21                           51
  Tiroch *et al*. \[[@CIT0204]\]            ABCB1               928        MI                        12 months   MACE                    NS      82                         29                           49
  **Thrombosis: ITGB3, P2Y12, IRS-1**                                                                                                                                                                    
  ONASSIST \[[@CIT0087]\]                   ITGB3               123/246    PCI (ST case/control)                 ST                      0.52    16                         0                            16
  FAST-MI \[[@CIT0158]\]                    ITGB3               2208       PCI+MI                    1 year      MACE                    NS      29                         2                            27
  Ziegler *et al*. \[[@CIT0215]\]           P2Y12               137        PAD                       2 years     Neurological event      4.02    31                         4                            27
  FAST-MI \[[@CIT0158]\]                    P2Y12               2208       PCI+MI                    1 year      MACE                    NS      25                         3                            25
  ONASSIST \[[@CIT0087]\]                   P2Y12               123/246    PCI (ST case/control)                 ST                      NS      32                         5                            27
  Angiolillo *et al*. \[[@CIT0169]\]        IRS-1               187        DM+CAD                    2 years     MACE                    2.88    31                         NN                           NN

AF -- atrial fibrillation, PCI -- percutaneous coronary intervention, NSTE-ACS -- non ST-elevation acute coronary syndrome, MACE -- major adverse cardiac events, MI -- myocardial infarction, ST -- stent thrombosis, PAD -- periphery artery disease, DES -- drug eluting stent, CAD -- coronary artery disease, TIMI -- thrombolysis in myocardial infarction, DM -- diabetes mellitus, NS -- not significant.

Due to a relatively low allele frequency (\< 1%), other identified *CYP2C19* variants (*\*3--\*8*) have only a minor impact on HPR \[[@CIT0149], [@CIT0158], [@CIT0159]\].

In contrast to *CYP2C19\*2, CYP2C19\*17* is a gain of function mutation leading to intensified activation of clopidogrel and so-called ultra-metabolizers with exaggerated bioactivation of clopidogrel. Data on whether there is an association of *CYP2C19\*17* with haemorrhagic events is conflicting, and to date not convincing \[[@CIT0120], [@CIT0155], [@CIT0156], [@CIT0160], [@CIT0161]\].

ABCB1 {#S20032}
-----

Thienopyridine absorption is mediated via the intestinal efflux transport pump P-glycoprotein encoded by the *ABCB1* gene (*MDR1*). The influence of different ABCB1 alleles is unclear. Some studies have shown that patients harbouring genetic variants in *ABCB1* (specifically homozygous for the C3435T variant), have lower levels of the active compound and higher rates of adverse clinical outcomes ([Table VI](#T0006){ref-type="table"}). However, this finding could not be confirmed in several subsequent studies. Further studies are needed to clarify the impact of this gene on the antiplatelet effect of clopidogrel \[[@CIT0034], [@CIT0162], [@CIT0163]\].

PON1 {#S20033}
----

*PON1* QQ192, a genetic variant in the gene encoding for the paraoxonase 1 (PON1) enzyme was linked to lower clopidogrel active metabolite concentrations in one study \[[@CIT0164]\], which however was not confirmed in the following studies \[[@CIT0091], [@CIT0150], [@CIT0165]--[@CIT0167]\] ([Table VI](#T0006){ref-type="table"}).

ITGB3 {#S20034}
-----

*ITGB3* that encodes the integrin β~3~ of the GP IIb/IIIa receptor has been linked with response variability of clopidogrel treatment and the risk of stent thrombosis \[[@CIT0087]\]. Again, these results are challenged by another study that could not confirm these observations \[[@CIT0158]\].

P2Y~12~ {#S20035}
-------

Genetic variations for the gene encoding the binding site for clopidogrel active metabolite on the P2Y~12~ receptor have shown a reduced efficacy of clopidogrel, but the clinical importance is doubtable \[[@CIT0087], [@CIT0158], [@CIT0168]\].

IRS-1 {#S20036}
-----

Polymorphism of the insulin receptor substrate (IRS)-1 have been shown to be associated with hyperactive platelets and increased risk for ischemic events in patients with type 2 DM and stable coronary artery disease \[[@CIT0169]\].

Studies investigating personalized antiplatelet treatment {#S0037}
=========================================================

The last decades of clopidogrel use have raised concerns that the "one dose fits all" approach is questionable in P2Y~12~-treated patients. There are numerous studies that linked HPR on clopidogrel to adverse ischemic events and gave credit to the need of platelet inhibition testing in case of clopidogrel. In multiple trials, it has been observed that ADP-antagonist induced platelet inhibition can be improved with increased clopidogrel loading and maintenance doses or simply by switching to novel compounds like prasugrel or ticagrelor. For example, increase to 150 mg maintenance dose of clopidogrel resulted in more intense inhibition of platelet aggregation than administration of the standard 75 mg dose in a subset of patients \[[@CIT0170]--[@CIT0172]\]. Nevertheless, it must be emphasized that increase in dosage is not sufficient in a number of patients, as it has been shown that even 900 mg loading doses of clopidogrel did not overcome HPR to clopidogrel in homozygous *CYP2C19\*2* allele carriers \[[@CIT0157]\]. Adjusted loading doses of clopidogrel according to platelet monitoring were shown to achieve a reduction of MACE without an increase of bleeding complications, however this strategy is not as sufficient as switch to prasugrel or ticagrelor \[[@CIT0079], [@CIT0173], [@CIT0174]\]. Concordant with this, intensified platelet inhibition with GP IIb/IIIa antagonists could be used as a "bridging strategy" at the time point of PCI \[[@CIT0175]\] and showed to lower the incidence of MACE without increased in-hospital bleeding rates in smaller studies \[[@CIT0176], [@CIT0177]\].

Most importantly, three randomized clinical trials (ARCTIC, *n* = 2,440; GRAVITAS, *n* = 2,200; and TRIGGER-PCI, *n* = 423) investigated if the outcome can be influenced using individualized antiplatelet strategy. In the GRAVITAS trial, clopidogrel treated patients with HPR received either standard dosing of clopidogrel or a second clopidogrel loading dose of 600 mg plus a maintenance dose of 150 mg. Within the 6-month follow-up, no significant differences in event rates could be shown in this patient population with a low-to-moderate thrombotic risk \[[@CIT0178]\]. The TRIGGER-PCI trial compared prasugrel versus clopidogrel in patients with low thrombotic risk. The trial had to be stopped prematurely, because an interim analysis indicated a lower than expected incidence of the primary endpoint. Therefore, no meaningful conclusions may be drawn regarding clinical events from this study \[[@CIT0179]\]. The ARCTIC trial included patients with low to moderate thrombotic risk with planed coronary stenting, that were randomised to bedside platelet function monitoring versus no monitoring. In the monitoring arm, antiplatelet therapy was intensified by increasing the dose of aspirin or an additional loading dose followed by an increased maintenance dose of clopidogrel, by additional treatment with a GP IIb/IIIa inhibitor or by switching to prasugrel. Adjustment of antiplatelet therapy based on platelet function monitoring did not lead to any improvement in the composite endpoint of coronary ischemic events \[[@CIT0180]\].

There are several possible explanations why these trials failed to show improved clinical outcome. Firstly, the three trials (GRAVITAS, TRIGGER-PCI, ARCTIC) only included low-to-moderate risk patients, whereas STEMI patients with a much higher ischemic risk were excluded. Moreover, in ARCTIC and GRAVITAS trials, only a minority of patients included had a non-ST-elevation-ACS (NSTE-ACS), whereas the TRIGGER-PCI trial included only patients with elective drug-eluting stent implantation during PCI and without procedural complications \[[@CIT0179]\]. It is likely that exclusion of high-risk patients may have accounted in part for the negative study results. Based on these findings one can argue that intensified antiplatelet treatment might not be beneficial in patients with a low-to-moderate risk for thrombotic events, but improve outcome in higher-risk patients or in those with a high risk for stent thrombosis \[[@CIT0181]\]. In line with this assumption, Aradi *et al*. could prove in a meta-regression analysis that the net clinical benefit of intensified P2Y~12~ inhibition depends on the baseline risk for stent thrombosis \[[@CIT0182]\]. This meta-analysis including 10 randomized trials with more than 4000 patients also proved that the intensified antiplatelet treatment was associated with a significant reduction in cardiovascular mortality, stent thrombosis and MI \[[@CIT0182]\]. The net clinical benefit of a personalized antiplatelet treatment also has been shown in the MADONNA study \[[@CIT0079], [@CIT0183]\]. Similarly, individualisation of dual antiplatelet therapy minimised early thrombotic events in an all-comers PCI population without increasing bleeding in an IDEAL registry \[[@CIT0184]\].

Individualised antiplatelet therapy -- algorithm approach {#S0038}
=========================================================

Due to the lack of prospective double-blind randomised studies demonstrating an improvement in clinical outcome by personalised antiplatelet therapy, there is no recommendation regarding a routine approach of individualised antiplatelet therapy. To date, there is only a class IIb recommendation for platelet function testing to facilitate the choice of P2Y~12~ inhibitor in selected patients on clopidogrel at high risk for thrombotic events \[[@CIT0185]\].

The novel platelet inhibitors prasugrel and ticagrelor have been shown to be superior concerning platelet inhibition and reduction of thrombotic events and for that it is feasible to use those compounds in all ACS patients, especially those at high risk. Nevertheless the ACC/AHA guidelines recommend either clopidogrel or ticagrelor or prasugrel in interventionally managed ACS (all of them received a class IB recommendation) and because of that an individualized antiplatelet therapy is conceivable. For that purpose it might be useful to use an algorithm for personalised antiplatelet therapy in patients who are at high thrombotic risk. This global risk algorithm is based on clinical (PREDICT score), biological (platelet function) and genetic (*CYP2C19\*2* carrier status) information \[[@CIT0186]\]. Nevertheless, this algorithm has not been tested prospectively yet.

Conclusions {#S0039}
===========

Although the tailored antiplatelet treatment monitored by platelet function testing seems to be feasible, the contradictory results of smaller registry studies and larger randomized trials with regards to outcome leave a big uncertainty. It is tempting to speculate that the different study populations, follow-ups, treatment strategies, study endpoints or time-points of blood sampling and therapy adjustment might disguise the real effect of tailored treatment \[[@CIT0181]\]. Therefore, further research is needed to define: patient populations, which would benefit from the tailored antiplatelet strategy in terms of net clinical outcome,which time points of platelet function testing are most predictive for outcome,whether multiple testing is necessary,whether genotyping adds useful information,how tailored antiplatelet strategy should be applied to patients with bleeding events,whether algorithm based approach to tailored anti-platelet strategy is feasible and improves net clinical outcome.
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